XXII - 22nd Century Group, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
2.73
+0.12 (+4.60%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close2.61
Open2.59
Bid2.71 x 1000
Ask2.75 x 4000
Day's Range2.55 - 2.78
52 Week Range1.92 - 4.44
Volume2,032,893
Avg. Volume2,079,873
Market Cap339.615M
Beta (3Y Monthly)1.16
PE Ratio (TTM)N/A
EPS (TTM)-0.10
Earnings DateNov 7, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.50
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents23 hours ago

    Edited Transcript of XXII earnings conference call or presentation 8-Nov-18 9:00pm GMT

    Q3 2018 22nd Century Group Inc Earnings Call

  • GlobeNewswireyesterday

    Bragar Eagel & Squire, P.C. is Investigating 22nd Century Group, Inc. (XXII) on Behalf of Stockholders and Encourages XXII Investors to Contact the Firm

    Bragar Eagel & Squire, P.C. is investigating potential claims against 22nd Century Group, Inc. (XXII).  Our investigation concerns whether 22nd Century has violated the federal securities laws and/or engaged in other unlawful business practices. On this news, the price of 22nd Century shares fell over 4%, closing at $2.45 per share on October 25, 2018. If you purchased or otherwise acquired 22nd Century shares and suffered a loss, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you.

  • PR Newswire2 days ago

    Scott+Scott Attorneys at Law LLP Announces Investigation into 22nd Century Group, Inc. (XXII)

    NEW YORK , Nov. 13, 2018 /PRNewswire/ --  Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, is investigating whether 22nd Century Group, ...

  • Analyzing 22nd Century Group’s Year-to-Date Performance
    Market Realist3 days ago

    Analyzing 22nd Century Group’s Year-to-Date Performance

    22nd Century Group (XXII) is a plant biotechnology company that’s focused on developing technologies to manage the nicotine content in tobacco plants and the cannabinoids in cannabis plants using gene editing and plant breeding technologies.

  • Associated Press8 days ago

    22nd Century: 3Q Earnings Snapshot

    The Williamsville, New York-based company said it had net income of 4 cents per share. The plant biotechnology company posted revenue of $6.3 million in the period. In the final minutes of trading on Wednesday, ...

  • Business Wire8 days ago

    22nd Century Files 2018 Third Quarter Report

    Company posts $6.3 million net income for third quarter; substantial MRTP application investments will result in fourth quarter submission to the FDA

  • GlobeNewswire13 days ago

    INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against 22nd Century Group, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 22nd Century Group, Inc. (“22nd Century Group” or “the Company”) (NYSE: XXII) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Seeking Alpha reported in an article published on October 25, 2018, that 22nd Century Group may be the subject of an active SEC investigation for allegedly engaging in a pump and dump scheme.

  • Business Wire17 days ago

    Glancy Prongay & Murray LLP Announces Investigation on Behalf of 22nd Century Group, Inc. Investors

    Glancy Prongay & Murray LLP announces an investigation on behalf of 22nd Century Group, Inc. investors concerning the Company and its officers’ possible violations of federal securities laws.

  • GlobeNewswire20 days ago

    SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of 22nd Century Group, Inc. (XXII) 

    NEW YORK, Oct. 26, 2018 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of 22nd Century Group, Inc..

  • Business Wire20 days ago

    INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of 22nd Century Group, Inc. Investors (XXII)

    Law Offices of Howard G. Smith announces an investigation on behalf of Stitch Fix, Inc. investors concerning the Company and its officers’ possible violations of federal securities laws.

  • Business Wire20 days ago

    INVESTIGATION ALERT REMINDER: The Schall Law Firm Announces it is Investigating Claims Against 22nd Century Group, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 22nd Century Group, Inc. (“22nd Century Group” or “the Company”) (NYSE: XXII) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Seeking Alpha reported in an article published on October 25, 2018, that 22nd Century Group may be the subject of an active SEC investigation for allegedly engaging in a pump and dump scheme.

  • Business Wire20 days ago

    22nd Century Group Comments on Grossly Misleading “Short and Distort” Article

    22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction and Very Low Nicotine tobacco, today commented on a highly deceptive article published yesterday by a self-professed short seller of the Company’s stock who launched his smear campaign in an effort to dupe shareholders into selling their shares of 22nd Century Group stock. After disparaging 22nd Century with misleading suppositions about an alleged Securities and Exchange Commission (SEC) enforcement proceeding against the Company, using innuendo in an attempt to diminish the strength of the positive press that 22nd Century has received, and attempting to link 22nd Century to stock promoters who have absolutely nothing to do with the Company, the author then disclosed that he is “short” the Company’s stock.

  • Business Wire21 days ago

    INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against 22nd Century Group, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 22nd Century Group, Inc. (“22nd Century Group” or “the Company”) (NYSE: XXII) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Seeking Alpha reported in an article published on October 25, 2018, that 22nd Century Group may be the subject of an active SEC investigation for allegedly engaging in a pump and dump scheme.

  • Business Wire21 days ago

    EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against 22nd Century Group, Inc.

    Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of 22nd Century Group, Inc. resulting from allegations that 22nd Century may have issued materially misleading business information to the investing public.

  • GlobeNewswire23 days ago

    New Research: Key Drivers of Growth for Genpact, Vistra Energy, 22nd Century Group, United States Steel, Zuora, and Tesla — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, Oct. 23, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Better Buy: GW Pharmaceuticals PLC vs. 22nd Century Group Inc.
    Motley Fool25 days ago

    Better Buy: GW Pharmaceuticals PLC vs. 22nd Century Group Inc.

    Which stock wins in a battle between these two biotechs?

  • FDA Lead Scientist Discusses 22nd Century’s SPECTRUM® Research Cigarettes in Public Webcast
    Business Wirelast month

    FDA Lead Scientist Discusses 22nd Century’s SPECTRUM® Research Cigarettes in Public Webcast

    22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company focused on tobacco harm reduction and Very Low Nicotine tobacco, announced today that on October 11, 2018, Dr. Lynn Hull, Lead Pharmacologist at the United States Food and Drug Administration (FDA) Center for Tobacco Products, held a webcast highlighting and summarizing the published science supporting the FDA’s efforts to dramatically reduce nicotine in all cigarettes sold in the United States. Entitled “Science to Inform a Tobacco Product Standard for the Level of Nicotine in Combusted Cigarettes,” Dr. Hull’s presentation featured prominently many independent clinical trials conducted with 22nd Century’s Very Low Nicotine Content (VLNC) SPECTRUM® research cigarettes.

  • Benzinga2 months ago

    High Times Buys DOPE Magazine For $11M: Here's Why And What It Means For The Cannabis Industry

    In the latest move toward consolidation in the industry, High Times announced Wednesday it has acquired DOPE Media in a split of cash and stock transaction valued at $11.2 million. "The acquisition of Dope Media will be a key building block as we continue on our mission to create brand-safe inventory for brands of all sizes," High Times CEO Adam Levin told Benzinga.

  • Business Wire2 months ago

    JAMA Publishes Greatly Anticipated Phase III Study Using 22nd Century’s SPECTRUM® Very Low Nicotine Content Cigarettes

    22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company focused on tobacco harm reduction and Very Low Nicotine tobacco, announced today that the Journal of the American Medical Association (JAMA) published results of a greatly anticipated independent clinical study investigating the effects of an immediate reduction in nicotine content of cigarettes versus a gradual reduction in nicotine content of cigarettes. Dr. Dorothy Hatsukami and other highly respected scientists used exclusively 22nd Century’s SPECTRUM® research cigarettes to conduct this study.

  • Why Are Insiders Pessimistic About 22nd Century Group Inc’s (NYSEMKT:XXII) Stock?
    Simply Wall St.3 months ago

    Why Are Insiders Pessimistic About 22nd Century Group Inc’s (NYSEMKT:XXII) Stock?

    22nd Century Group, Inc., a plant biotechnology company, provides technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and cannabinoids in hemp/cannabisRead More...

  • Business Wire3 months ago

    22nd Century Receives Order for 3.6 Million SPECTRUM® U.S. Government Research Cigarettes

    22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company focused on tobacco harm reduction and Very Low Nicotine tobacco, announced today that the National Institute on Drug Abuse (NIDA), the U.S. Food and Drug Administration (FDA), and public health researchers have requested a new, significant quantity of 22nd Century’s proprietary SPECTRUM® research cigarettes. In coordination with NIDA, FDA, and others, RTI International has submitted an order to 22nd Century for 3.6 million SPECTRUM® research cigarettes.

  • Is 22nd Century Group, Inc. a Buy?
    Motley Fool3 months ago

    Is 22nd Century Group, Inc. a Buy?

    The FDA might help this biotech corner the U.S. tobacco market.

  • Associated Press3 months ago

    22nd Century: 2Q Earnings Snapshot

    On a per-share basis, the Williamsville, New York-based company said it had a loss of 5 cents. The plant biotechnology company posted revenue of $6.9 million in the period. In the final minutes of trading ...

  • Business Wire3 months ago

    22nd Century Files 2018 Second Quarter Report

    Company significantly increases spending and strategic initiatives in support of MRTP application and FDA’s ANPRM for reduced nicotine cigarettes. 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is focused on tobacco harm reduction, Very Low Nicotine tobacco, and hemp/cannabis research, announced today the Company’s second quarter 2018 financial results. 22nd Century will provide a business update for investors on a conference call to be held Wednesday, August 8, 2018, at 4:00 PM (Eastern Time).